+ Follow San Antonio Breast Cancer Symposium Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1674888
[Title] => Can aspirin prevent breast cancer?
[Summary] => A large randomized controlled trial of aspirin for breast cancer prevention is warranted in light of new evidence that aspirin use shows a strong independent inverse relationship with mammographic breast density, declared at the San Antonio Breast Cancer Symposium.
[DatePublished] => 2017-02-26 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 674454
[Title] => Lasofoxifene shown to sharply reduce incidence of breast cancer
[Summary] => The investigational selective estrogen-receptor modulator laso-foxifene is shaping up as a PEARL of a drug for the prevention of breast cancer.
[DatePublished] => 2011-04-10 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[2] => Array
(
[ArticleID] => 639200
[Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
[Summary] => TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
[DatePublished] => 2010-12-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 551569
[Title] => Greater chances of cure for patients with breast cancer
[Summary] => Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
[DatePublished] => 2010-02-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Lifestyle
[SectionUrl] => cebu-lifestyle
[URL] =>
)
[4] => Array
(
[ArticleID] => 246270
[Title] => Breast cancer drug boosts survival
[Summary] => At least 1,500 lives could be saved every year if a drug used to treat terminal breast cancer cases is given early in the disease.
The Breast Cancer International Research Group (BCIRG) said docetaxel (distributed by Aventis Pharma Inc.) significantly improved the survival rate of women with early-stage breast cancer and reduced their risk of a relapse compared with a standard treatment. This implies that docetaxel is a potential life-saver and should not only be used in terminally ill patients to buy extra time.
[DatePublished] => 2004-04-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
San Antonio Breast Cancer Symposium
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1674888
[Title] => Can aspirin prevent breast cancer?
[Summary] => A large randomized controlled trial of aspirin for breast cancer prevention is warranted in light of new evidence that aspirin use shows a strong independent inverse relationship with mammographic breast density, declared at the San Antonio Breast Cancer Symposium.
[DatePublished] => 2017-02-26 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 674454
[Title] => Lasofoxifene shown to sharply reduce incidence of breast cancer
[Summary] => The investigational selective estrogen-receptor modulator laso-foxifene is shaping up as a PEARL of a drug for the prevention of breast cancer.
[DatePublished] => 2011-04-10 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[2] => Array
(
[ArticleID] => 639200
[Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
[Summary] => TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
[DatePublished] => 2010-12-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 551569
[Title] => Greater chances of cure for patients with breast cancer
[Summary] => Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
[DatePublished] => 2010-02-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Lifestyle
[SectionUrl] => cebu-lifestyle
[URL] =>
)
[4] => Array
(
[ArticleID] => 246270
[Title] => Breast cancer drug boosts survival
[Summary] => At least 1,500 lives could be saved every year if a drug used to treat terminal breast cancer cases is given early in the disease.
The Breast Cancer International Research Group (BCIRG) said docetaxel (distributed by Aventis Pharma Inc.) significantly improved the survival rate of women with early-stage breast cancer and reduced their risk of a relapse compared with a standard treatment. This implies that docetaxel is a potential life-saver and should not only be used in terminally ill patients to buy extra time.
[DatePublished] => 2004-04-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
December 16, 2010 - 12:00am
February 22, 2010 - 12:00am
